Infants and young children are the groups at greatest risk for severe disease and mortality following acquisition of Plasmodium falciparum infection. Recent large clinical trials with a candidate malaria vaccine have demonstrated very limited protection of only short duration. We have previously demonstrated in mice that a protein vaccine in which the chemokine macrophage inflammatory protein 3α is genetically fused to the minimally truncated circumsporozoite protein of P. falciparum (MCSP) elicits extended high level protection against sporozoite challenge in a mouse model system. In the current study we determined that the research grade formulation of a clinically approved vaccine adjuvant, MF59, elicited greater antibody responses in mice than the previously employed adjuvant, poly(I:C). Use of the MF59 vaccine also expanded the range of IgG subtypes elicited by vaccination. Two immunizations of infant rhesus macaques at one and two months of age with the MCSP/MF59 regimen elicited antibody concentrations that were sustained for 18 weeks at levels that provided passive protection of mice challenged with large sporozoite inocula. The efficacy of this vaccine in a relevant nonhuman primate model indicates its potential usefulness for the analogous high risk human population.
The World Health Organization reported in 2017 that after many years of decline in malaria incidence, the number of estimated cases increased from 211 million in 2015 to 216 million in 2016 1 . This increase, and emerging evidence of increased resistance to antimalarial drugs 2, 3 , indicate the continued need for cost-effective strategies to control the epidemic. The development of an effective malaria vaccine would obviously address this need. However, despite clear evidence from animal model systems that sufficient concentrations of specific antibody can protect against malaria infection, candidate vaccines tested in human populations have failed to achieve and sustain the levels of protection expected from an effective vaccine. The inadequacy of the observed protection has been particularly apparent in the infants and young children who are at greatest risk of severe malaria infection 4 . enhancement of the antibody response compared to that observed with vaccine constructs not employing the chemokine component Luo, 2014 #2978; Luo, 2017 #3226 ].
In the current study we have compared in the mouse model system the immune responses and protection observed using clinically approved adjuvants in addition to the the poly (I:C) adjuvant previously demonstrated to be effective. These studies indicated that the clinically approved adjuvants elicited more profound antibody responses than poly (I:C). We then examined in a pilot study the ability of this vaccine construct used with a clinically approved adjuvant to elicit protective immune responses in one and six month old macaques, representing the age groups in humans most vulnerable to severe malaria infection. Our studies indicate that this vaccine construct is highly immunogenic in infant and juvenile macaques.
Materials and Methods

Animals
Six-to eight-week-old female C57BL/6 (H-2b) mice were purchased from Charles River Laboratory (Charles River Laboratories, Inc, Wilmington, MA) and maintained in a pathogen-free micro-isolation facility in accordance with the National Institutes of Health guidelines for the humane use of laboratory animals. One and six months Rhesus Macaques were housed at the Johns Hopkins University Research Farm. All experimental procedures involving mice and monkeys were approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University and determined to be in accordance with the guidelines outlined in the Animal Welfare Act, federal regulations, and the Guide for the Care and Use of Laboratory Animals.
Construction, expression, production and purification of recombinant proteins
Recombinant P. falciparum CSP (3D7) and CSP fused with human MIP-3α proteins were prepared as previously described 8 . The codon-optimized CSP DNA sequence containing deletions of the N-terminal 20 aa signaling sequence and the C-terminal 23 aa anchor region fused with human MIP-3α was used to express MIP-3α-CSP chimeric protein (MCSP). Twenty-two NANP repeats were included in the truncated CSP. CSP and MCSP sequences were cloned into pET-47b (Novagen Inc., Madison, WI) fused with 6XHis. The proteins were expressed in BL21 DE3 competent cells (New England Biolabs, Ipswich, MA). Protein purification was undertaken using nickel-affinity chromatography (Qiagen, Valencia, CA, USA) and endotoxin was removed by twophase extraction with Triton X-114 9 . Protein concentration was measured by Bradford assay (BioRad, Hercules, CA). Endotoxin concentration was determined using the ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit (Genscript, NJ). All protein used for immunization had final endotoxin levels below 10EU/ml.
Animal immunization
C57BL/6 mice were immunized with 20 µg (50 µl) purified MCSP in PBS with the adjuvant polyinosinic-polycytitdlic acid (Poly (I:C)), Aluminium hydroxide gel (Alum), , or the squalene-based oil-in-water nano-emulsion (MF59, available in research grade as Addavax). All adjuvants were obtained from Invivogen, San Diego, CA. For Poly (I:C), Alum or MF59 formulation, 50 µg adjuvant was mixed with 50 µl antigen, and the final volume ratio was 1:1. The mixture was administered intramuscularly in both anterior tibialis muscles in a total volume of 50 µl per leg. Mice were immunized twice at a 3
week interval. Rhesus Macaques were immunized with 50 µg or 250 µg purified MCSP in 250 µl PBS. The antigen was mixed with same volume of MF59 and administered intramuscularly in both leg muscles in a total volume of 250 µl per leg. Macaques were immunized according to schedules described in the Results section.
Antibody titer by ELISA
Humoral immune responses to the immunodominant B cell epitope of the relevant CSP protein were measured using a previously described method [Luo, 2014 #. Briefly, ELISA plates were coated with 2 µg of recombinant PfCSP overnight at room temperature (RT). Plates were blocked with 2% BSA for 30 min at RT and then serially diluted serum samples were added and incubated for 2 h. After washing six times, peroxidase labeled goat anti-mouse IgG or goat anti-human IgG antibodies (Santa Cruz Biotechnology Inc, Dallas, TX) was added at a dilution of 1:4,000 and incubated at RT for 1 h. After washing six times, ABTS Peroxidase substrate (KPL, Gaithersburg, MD) was added for development and incubated for 1 h. The data were collected using the Synergy HT (BioTek Instruments, Inc, Winooski, VT). The endpoint ELISA titer is reported as the highest dilution of serum at which the average absorbance was twice the value obtained using pre-immunization serum.
Parasites for challenge
Transgenic P. berghei sporozoites [Persson, 2002 #3069] were used for challenge.
Sporozoites were obtained by hand dissection of salivary glands of Anopheles stephensi mosquitoes maintained in the Johns Hopkins Malaria Research Institute insectary. The isolated sporozoites were suspended in HBSS medium containing 1% normal mouse serum. Challenges to evaluate vaccine effect on hepatic parasite load were accomplished by tail vein injection of 5 x 10 3 sporozoites. In one experiment, mice were challenged with exposure to five infectious mosquitoes for 10 minutes.
Real-time PCR for liver stage parasites
Approximately 40 hours after sporozoite challenge, livers of the mice were harvested and homogenized, and RNA was extracted. After reverse transcription (Applied Biosystems, Foster city, CA), Real-time PCR was used for the detection and quantification of the liver stage of Plasmodium parasites. Two pairs of specific primers were designed to amplify the parasite 18s rRNA sequence. The forward primer was 5'-TGGGAGATTGGTTTTGACGTTTATGT-3' and the reverse primer was 5'-AAGCATTAAATAAAGCGAATACATCCTTAC-3'. Values were normalized against measurements of mouse actin mRNA in the same samples. The primers used for mouse actin were as follows: 5'-GTCCCTCACCCTCCCAAAAG-3' (forward) and 5'-GCTGCCTCAACACCTCAACCC-3' (reverse). The reactions were performed in a final volume of 20 µl using SYBR green PCR Master Mix (2X) from Applied Biosystems and processed with ABI StepOne Real-time PCR system (Applied Biosystems).
Passive antibody or serum transfer
Rhesus Macaques were immunized with 50 or 250 µg MCSP and 250 µl MF59 at the indicated frequencies and intervals (see Results Section). Four weeks after the second immunization, macaque blood was collected and serum was isolated. All samples were pooled and some of the sera were used to obtain purified IgG, using protein A affinity chromatography (GE Healthcare, NJ). IgG from pooled samples that were collected from the macaques before immunization was purified as the control for passive antibody transfer. C57BL/6 mice were injected I.V. with 200µl purified anti-CSP IgG or immune sera or control IgG or sera. Thirty minutes following injection of antibody or sera, mice were inoculated via tail vein with 5 x 10 3 transgenic P. berghei sporozoites. Liver stage sporozoite copy number was measured 48h following infection.
Statistical analysis
Linear regression analysis was used to compare the antibody concentration curves from mice receiving different adjuvants. An ANOVA analysis was used to compare antibody concentrations at given time points and liver sporozoite copy numbers following challenge. Prism statistical analysis and graphing software (GraphPad Software, Inc., San Diego, CA) was used for all studies.
Results
Evaluating the efficicacy of different adjuvants in enhancing the anti-CSP humoral immune response. While vaccine adjuvant development is an active research area, only alum and MF59 have been approved by the US FDA for use in commonly employed parenterally administered vaccines. We first compared in C57Bl/6 mice the CSP-specific humoral immune responses elicited by the MCSP vaccine in combination with these two adjuvants and the previously studied poly (I:C) 8 . The results ( Figure 1 ) indicate that the most profound response is elicited by MF59, with a mean OD 405 value significantly greater than that observed with poly (I:C) at all time points after the priming immunization (p<0.001 for all points). However only at time points at or beyond 13 weeks after the primary immunization was the MF59 response significantly greater than that observed with use of the alum adjuvant (p<0.05).
We next examined the impact of the different adjuvants on the IgG subtype of the elicited antibody response ( Figure 2 ). For each adjuvant there were significant differences in the magnitude of the responses among the different subclasses (p<0.05), except for IgG3 where the alum and poly(I:C) responses were statistically equivalent (p=0.12). Although the responses observed with the use of each of the different adjuvants was statistically distinct, the most striking difference among the adjuvants was the markedly reduced IgG2b and IgG2c responses observed with use of the alum adjuvant.
Efficacy of MIP3α-CSP vaccine combined with different adjuvants in protecting mice
from mosquito bite challenge. To characterize at 22 weeks post-the final of two immunizations the protective efficacy of the different combinations of adjuvant and vaccine, immunized or non-immune C57Bl6 mice were challenged by exposure for 10 minutes to 5 Anopheles stephensi mosquitoes infected with transgenic P. berghei sporozoites. Sporozoite copy numbers determined by qRT-PCR indicated no statistically significant difference among the adjuvant groups in the protective efficacy elicited ( Figure 3 ). However all groups receiving vaccine plus adjuvant had highly significant reductions of at least 78% in the liver sporozoite copy number compared to unimmunized mice.
Immunogenicity of MCSP vaccine and MF59 adjuvant in one month old macaques.
Although protection achieved by vaccination of C57Bl/6 mice challenged at 22 weeks did not differ significantly between the MF59 and alum adjuvants that are used in FDA approved vaccines, the consistently higher antibody concentrations achieved with MF59 and its ability to elicit a broader subclass response led to its selection for use in subsequent studies. One issue in vaccine development is whether responses in mice can be recapitulated in the clinical setting. Non-human primates, particularly Old World primates such as rhesus macaques, have immune systems that are most homologous to humans 10-14 .. To address the immunogenicity of this vaccine construct in a setting relevant to the groups at high risk from malaria, we initiated an immunization protocol in infant, one month old, and juvenile, six month old, macaques, using one of two dosing regimens. In each of the age groups two macaques received a priming 50 µg dose of the MCSP vaccine construct and 250 µg of the MF59 adjuvant followed by two subsequent immunizations with the same dosing at monthly intervals. The two other macaques in each age group macaques received a priming immunization with 250 µg of vaccine and 250 µg of the MF59 adjuvant followed one month later by a second immunization using the same vaccine and adjuvant dose. Figure 4 Control mice received pre-immune macaque sera or IgG in volumes equivalent to that received by recipients of immune sera or IgG. As indicated in Figure 5 , the mice with reciprocal anti-CSP ELISA titers as low as 64,000 still had significant reduction in their liver sporozoite load.
Discussion
In the current study, we have examined in C57Bl/6 mice and infant and juvenile Rhesus macaques the efficacy of a malaria vaccine platform that had previously demonstrated, using a different adjuvant, extended protection efficacy in a murine malaria challenge system. A distinctive feature of the vaccine platform is its fusion of vaccine antigen to the chemokine MIP3α, which serves as the ligand for CCR6, expressed predominantly on iDC. The MF59 adjuvant selected for study in the macaques was chosen based on studies in the mouse model system and the fact that it has been approved as an adjuvant for clinical use with other vaccines by the US FDA.
The vaccine construct and adjuvant used in these studies target the earliest steps in the encounter between the host immune system and the foreign antigen. Those steps include the attraction of antigen presenting cells to the site of immunization, attributable to the chemoattractant properties of both MF59 15 A recent study of responses in humans to a candidate HIV-1 vaccine found that MF59 elicited higher responses in human infants than those observed in adults 25 . This observation is consistent with our findings. Even with the small sample size of our pilot study, the maximum antibody response obtained seven weeks after the primary immunization, three weeks after the second immunization, was significantly higher in macaques initially immunized at one month of age compared to those initially immunized at six months of age (p=0.03). Importantly the HIV infant immunization study demonstrated that the higher responses observed in infants, while unexplained, was not simply attributable to differences in the per body weight dose of vaccine. Two different dosing regimens were used in our macaque immunization studies, but across both age groups dose did not significantly affect the magnitude of the antibody response at 7 weeks (p=0. 13 ), suggesting that an immunogenicity threshold had been reached with the 50 µg vaccine dose.
Macaques were chosen for our nonhuman primate study because their immune ontogeny more closely parallels that of humans than does that of rodents or that of the New World monkeys that have been used as non-human primate challenge models of malaria bloodstream infection [10] [11] [12] [13] [14] . A recent study comparing the immunogenicity of two formulations of a candidate sporozoite-targeted vaccine demonstrated that different conclusions might be reached using mouse vs macaque models for analysis of CSP immunogenicity 26 . Pre-erythrocytic stage P. falciparum challenge models using macaques have been unsuccessful, and efforts to develop Aotus monkey based challenge systems have also proved problematic. Reports from two laboratories indicated success with sporozoite transmission in this species 27, 28 . However, for sporozoite transmission to Aotus monkeys, splenectomy is required and, according to these reports, successful transmission occurs with varying frequency, achieves highly variable levels of parasitemia, has wide variation in the pre-patent period, is frequently accompanied by clearing of parasitemia in the non-immune host and requires use of parasites that have been obtained from relatively recent human infection for best results 27 . No studies using this model have been published since 2009.
To evaluate the protective efficacy of the antibody concentrations attained with macaque immunization we determined the quantity of passively transferred IgG or serum to be passively administered to duplicate the concentrations in macaques.
Purified and concentrated IgG was required to reproduce in the mice the higher concentrations observed in the macaques. Passively immunized mice were challenged with inocula of transgenic P. berghei sporozoites, far exceeding that which would be encountered in the clinical setting, to ensure liver infection at a level that would facilitate comparison of the efficacy of the different concentrations.
The results indicate that this vaccine formulation, which employs clinically approved adjuvants, can elicit protective concentrations of antibody in infant and juvenile macaques. Further studies are required to identify the immunization protocols that will be optimal for eliciting sustained protective immunity in this immunological setting, which closely parallels that of humans at greatest risk for adverse outcomes following malaria 
Fig. 2 Generation of anti-CSP antibody of different isotypes after immunization
with different adjuvants. C57BL/6 mice were immunized twice with 20 µg MCSP plus different adjuvants at a three week interval. Mouse sera were obtained 3 weeks after the last immunization for ELISA, performed as in Fig. 1 , except that isotype specific secondary antibodies were used to determine concentrations of IgG1, IgG2b, IgG2c and IgG3. Within each subtype the results comparing the different adjuvants differ significantly (p<0.02) for all comparisons except MF59 vs. poly (I:C) for IgG2c, which did not differ significantly. mice were immunized twice with 20 µg MCSP plus different adjuvants at a three week interval. Twenty-two weeks after the final immunization, mice were exposed for 10 minutes to 5 mosquitos infected with transgenic P. berghei sporozoites. Parasite-specific rRNA levels in the liver were determined by quantitative RT-PCR on samples obtained 48 hours post challenge. All qPCR results were normalized against the expression of mouse β-actin. Percentage reduction in liver sporozoite copy numbers did not differ significantly among immunized mice (p>0.5) and all immunized groups differed significantly from control mice (p<0.001). P=0.006 P=0.025 P=0.05
